Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that it bought back 650,000 ordinary shares on 19 March 2026 through BNP Paribas as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were acquired at a volume‑weighted average price of 1,954.04p, within a range of 1,944.50p to 1,975.50p per share.
The shares will be held as treasury shares. Since 17 February 2026, GSK has purchased 12,771,521 ordinary shares under this programme. After this transaction, the company holds 252,662,615 shares in treasury and has 4,063,508,150 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.22% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reports that the US FDA has approved Lynavoy (linerixibat) to treat cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). Lynavoy is an ileal bile acid transporter (IBAT) inhibitor and is the first medicine approved in the US specifically for this indication.
The approval is supported by the phase III GLISTEN trial, which met its primary and key secondary endpoints, showing significant, rapid (by week two) and sustained (over 24 weeks) reductions in itch and itch-related sleep interference versus placebo. The most common side effects were diarrhoea and abdominal pain, generally mild to moderate.
GSK previously signed a licence agreement for Alfasigma S.p.A. to acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, with this transaction still subject to customary regulatory clearances. Regulatory reviews for linerixibat are also underway in the EU, UK, Canada and China, and the drug has Orphan Drug Designation in the US and Japan and priority review in China.
GSK plc reports that, acting through BNP Paribas, it purchased 836,000 of its ordinary shares on 18 March 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at a volume-weighted average price of 1,980.45p, within a range from 1,946.00p to 2,013.00p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has repurchased a total of 12,121,521 ordinary shares. Following the latest transaction, GSK will hold 252,012,615 ordinary shares in treasury and have 4,064,158,150 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, in line with DTR 5.5.1R, the voting rights attributable to treasury shares represent 6.20% of the total. The filing also provides detailed trade-by-trade data, including prices and volumes across London Stock Exchange and Cboe Europe order books (CHIX and BATE).
GSK plc filed a report describing a small insider share purchase. Chief People Officer Diana Conrad acquired American Depositary Shares under a GSK pension plan. She bought 12.430 ADS at a price of $54.4100 per ADS on 2026-03-16 on the New York Stock Exchange.
GSK plc reports that, through BNP Paribas, it repurchased 732,112 ordinary shares of 31¼ pence each on 17 March 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,002.00p and 2,036.00p, with a volume‑weighted average of 2,016.45p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 11,285,521 ordinary shares. After this transaction, it holds 251,176,615 shares in treasury and has 4,064,994,150 shares in issue, which is also the total number of voting rights. Treasury shares represent 6.18% of voting rights.
GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. The transaction involved 129.152 ADS at a price of $53.3900 per ADS on 2026-03-13 on the New York Stock Exchange.
These are plan-related notional ADS rather than a standard open-market purchase, reflecting additional equity-linked compensation within her executive savings account.
GSK plc reports that it repurchased 628,000 ordinary shares on 16 March 2026 under its existing share buyback programme, acting through BNP Paribas. The shares were bought at prices between 2,026.00p and 2,052.00p per share, with a volume‑weighted average price of 2,035.82p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 10,553,409 ordinary shares. After this transaction, GSK holds 250,444,503 shares in treasury and has 4,065,726,262 ordinary shares in issue, all carrying voting rights.
The total number of voting rights in GSK is stated as 4,065,726,262, and the company notes that treasury shares represent 6.16% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that on 13 March 2026 it repurchased 445,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,027.00p to 2,060.00p per share, with a volume‑weighted average price of 2,041.70p.
The shares bought will be held as treasury shares. Since 17 February 2026, GSK has repurchased 9,925,409 ordinary shares. After this transaction, it holds 249,816,503 shares in treasury and has 4,066,354,262 ordinary shares in issue and voting rights, with treasury shares representing 6.14% of voting rights.
GSK plc reports that the US FDA has expanded the approved age indication for its RSV vaccine Arexvy to adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by RSV. Arexvy was previously approved in the US for adults 60 and older, and for adults 50-59 at increased risk. GSK notes that an estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, and that RSV drives about 17,000 hospitalisations and 1.97 million outpatient visits annually among adults 18-49 years. The label expansion is supported by a Phase IIIb trial showing a non-inferior immune response versus adults 60 and above, with a safety profile consistent with earlier Phase III data.
GSK plc reports that, on 12 March 2026, it repurchased 790,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,016.00p to 2,057.00p per share, with a volume‑weighted average price of 2,036.73p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 9,480,409 ordinary shares. Following this latest transaction, the company holds 249,371,503 shares in treasury and has 4,066,797,319 ordinary shares in issue, giving a total of 4,066,797,319 voting rights.
GSK states that, in line with DTR 5.5.1R, 6.13 per cent of its voting rights are now attributable to ordinary shares held in treasury.